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Abstract
Background
The effectiveness of an intervention in clinical practice is often reduced compared to the
efficacy demonstrated in a randomised controlled trial (RCT). In this comparative effective-
ness study, the RCT-proven efficacy of a diabetes education programme for type 1 diabetic
patients (PRIMAS) was compared to the effectiveness observed in an implementation trial
(IT) under routine care conditions.
Methods
75 patients with type 1 diabetes received PRIMAS through an RCT, whereas 179 patients
were observed in an implementation trial. Baseline characteristics and treatment outcomes
at the 6-month follow-up (improvement of HbA1c, hypoglycaemia problems, and diabetes-
related distress) were compared.
Results
At baseline, the type 1 diabetic patients in the RCT had a significant longer diabetes dura-
tion (18.7±12.3 vs. 13.8±12.7 yrs., p = .005), lower self-efficacy scores (21.9±4.7 vs. 23.7
±6.1, p = .02) and a greater number of diabetes complications (0.8±1.3 vs. 0.4±0.9, p = .02).
After 6 months, PRIMAS achieved comparable effects under RCT and implementation trial
conditions, as demonstrated by improvement in HbA1c (-0.36%±1.1 vs. -0.37±1.2; Δ -0.01,
95% CI -0.33 to 0.31) and hypoglycaemia unawareness (-0.5±1.4 vs. -0.3±1.4; Δ 0.18, 95%
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CI -0.21 to 0.57). The likelihood of clinical improvement did not depend on the trial setting
(RCT vs. IT: OR 1.18, 95% CI 0.60 to 2.33). The participants with worse glycaemic control
(OR 1.40, 95% CI 1.02 to 1.92), hypoglycaemia problems (OR 2.13, 95% CI 1.53 to 2.97) or
elevated diabetes distress (OR 1.40, 95% CI 1.03 to 1.89) had a better chance of clinical
improvement.
Conclusions
The effectiveness of PRIMAS under routine care conditions was comparable to the efficacy
demonstrated in the RCT. Clinical improvement was independent of the setting in which
PRIMAS was evaluated. The PRIMAS education programme for type 1 diabetes can be
delivered under conditions of routine care without a loss of effectiveness, compared to its
original evaluation in an RCT.
Introduction
Structured diabetes education has been an integral part of the treatment of type 1 diabetes for
decades [1–6]. The objectives of structured diabetes education are multifaceted as they range
from improving glycaemic control and problems with hypoglycaemia to reducing diabetes-
related emotional distress [7]. In summary, diabetes education aims to empower people with
type 1 diabetes to manage their diabetes treatment (especially intensive insulin therapy) and
the emotional challenges associated with their chronic disease by themselves [8]. Considering
these different objectives, diabetes education and treatment programmes are complex interven-
tional measures.
In addition to the transfer of knowledge and skills, the enhancement of diabetes self-man-
agement is an important component of modern diabetes education programmes. Therefore,
diabetes education programmes should include various tools or components that enable active
self-management, such as discussion of individual attitudes and barriers and how to cope with
perceived problems of living with diabetes as well as practicing skills to deal with the challenges
of diabetes in daily life.
Adding to the complexity, the outcomes of structured diabetes education for type 1 diabetes
not only depend on education itself but also on several circumstantial factors. These include
the diabetes regimen, the knowledge and skills of the health care professionals who deliver the
diabetes education, and the motivation of the patients to participate in the diabetes education
and to implement new skills into their daily routine [9].
Therefore, structured diabetes education and treatment programmes not only are consid-
ered to be complex interventions but are also complex to evaluate as their efficacy relies on a
number of different, partially fixed circumstantial factors. The multiple components of diabetes
education cannot be tested separately. In addition, other design requirements that relate to the
evaluation of pharmacological interventions, such as double-blind delivery of the intervention,
are not possible in the evaluation of diabetes education.
For these reasons, the U.K. Medical Research Council [10–12] established an algorithm for
the development and evaluation of complex interventions. This algorithm was applied to the
development and evaluation of diabetes education programmes by Mühlhauser & Berger
[13]. The algorithm describes how complex intervention should be developed; theoretical con-
siderations should be considered first, and then a modelling phase, feasibility studies, and a
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randomised controlled trial (RCT) should follow to demonstrate the overall efficacy of the
complex intervention. In addition to the primary test of the efficacy of structured diabetes edu-
cation programmes through an RCT, evaluation of the implementation of new diabetes educa-
tion programmes in clinical care settings should be a key feature of the evaluation of such
complex interventions.
According to many health care research trials, there is a gap between the efficacy in RCTs
and the effectiveness in clinical practice [14–16]. Therefore, implementation trials (ITs) con-
ducted as part of comparative effectiveness research [17] that compare the efficacy of diabetes
education conducted under more strict conditions of an RCT with the effectiveness of educa-
tion conducted under less strict conditions of routine care are necessary. Possible differences
between the results obtained using an RCT and IT could be due to differences in sample com-
position related to the stricter inclusion and exclusion criteria of RCTs. Additionally, the
implementation of a structured intervention in routine care is frequently associated with
reduced standardisation of the intervention due to differences in the clinical settings in which
the complex intervention is used.
We recently developed a treatment and education programme for people with type 1 diabe-
tes (PRIMAS) that aimed to improve glycaemic control by enhancing self-management. PRI-
MAS was evaluated in an RCT, and its efficacy was demonstrated [18].
Following the suggestions of Mühlhauser & Berger [13], an IT was conducted to evaluate
the effectiveness of PRIMAS under routine care conditions.
The aim of this comparative effectiveness study was to compare the baseline characteristics
and treatment outcomes of PRIMAS participants when the programme was conducted under
the conditions of an RCT or in a routine care setting in an IT. Possible differences between the
RCT and IT refer to the selection of participants, the medical problems that indicate a partici-
pation in a structured diabetes education programme, and treatment outcomes.
Materials and Methods
Development of the PRIMAS intervention
PRIMAS, a new structured diabetes education and treatment programme for type 1 diabetes,
was developed according to the criteria established by the U.K. Medical Research Council. Dur-
ing the theoretical phase, the shift from more knowledge-driven educational concepts to more
self-management-oriented educational concepts greatly influenced the conceptualisation of
PRIMAS. Furthermore, PRIMAS also reflects the change from educational concepts aimed at
optimal compliance with treatment recommendations to a concept that is focused on empow-
ering people to actively participate in treatment decisions. New technologies, such as advances
in continuous glucose monitoring as well as new insulin and CSII devices, were also an impor-
tant aspect in the conceptualisation of the PRIMAS programme.
During the modelling phase, formative evaluation techniques were applied to introduce and
discuss the new educational material with diabetologists and diabetes educators. Pilot testing of
the new educational material was carried out in certain diabetologist practices to improve and
refine the concepts and material.
During the evaluation phase, an RCT was conducted to investigate the impact of PRIMAS
on glycaemic control and a variety of other outcome variables compared to that of an estab-
lished programme for type 1 diabetes. The results of the RCT were published in 2013 [18].
Subjects
The eligibility criteria for the RCT and IT are reported in Table 1. In the RCT, the recruitment
of patients was based on the inclusion criteria, whereas in the IT sample, recruitment was
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based on clinical indication, as defined by the treating physician. These indications typically
include a lack of previous diabetes education, considerable passage of time since the last educa-
tion, suboptimal control (elevated HbA1C levels or hypoglycaemia problems) despite opti-
mised treatment, or psychosocial problems that impair coping with diabetes. The IT clearly
had less inclusion criteria than the RCT. With the exception of a duration of type 1 diabetes of
more than 1 month, there were no specific inclusion criteria for the IT. Specifically, there were
no age limits or eligibility criteria based on glycaemic control or BMI in the IT. Patients in both
trials had to possess the language skills to follow diabetes education and the need for diabetes
education according to the assessment of the treating physician.
Exclusion criteria for both the RCT and IT included current psychological or psychiatric
disorder (under treatment), dementia or severe cognitive impairment, severe somatic disease
(that would prevent regular participation in the education course), and pregnancy.
Trial settings
There were 2 measurement points in the RCT and IT. The first measurement took place at
baseline prior to the start of the education course—in case of the RCT the measurement took
place before randomisation. The second measurement was conducted 6 months after the end
of the education course. Both measurements were conducted at the site of each patient’s diabe-
tes care practice. The timing of the follow-up assessment was in line with current routine care
for people with type 1 diabetes; routine care guidelines recommend visits every 3 months for
HbA1c measurement. In the IT setting, patients were asked to complete questionnaires at their
second routine care visit after participation in the PRIMAS course. Furthermore, a blood sam-
ple was drawn for the measurement of HbA1c in a central laboratory (the same laboratory as
that used in the RCT). Hence, patients of the IT did not receive care that differed from the
usual care of people with type 1 diabetes. In the RCT, specialised diabetes care practices at the
secondary care level (n = 23), including diabetologists and certified diabetes educators, were in
charge of the conduction of PRIMAS. The duration of the PRIMAS course (12 lessons) in the
RCT was predefined, with 2 lessons each week. In the IT, primary (n = 21) and secondary care
level (n = 21) practices conducted PRIMAS. No predefined course duration was given in the
IT. In addition, a high level of standardisation and fidelity was established in the RCT, such as
monitoring the conduction of PRIMAS as well as the conduction of the study. Practices in the
IT did not receive any special training in conducting PRIMAS.
The RCT began in September 2010 (first patient in) and ended in January 2012 (last patient
out). The IT began in September 2012 (first patient in) and ended in November 2013 (last
patient out).
Outcome measures
The reduction of HbA1c within 6 months of the termination of the intervention was the pri-
mary outcome of the RCT [18]. For the present analysis, the HbA1c reduction achieved in the
Table 1. Inclusion criteria for the RCT and IT.
RCT IT
type 1 diabetes type 1 diabetes
age 18 and 75 years -
diabetes duration >1 month diabetes duration >1 month
BMI >20 and <40 kg/m2 -
HbA1c 7.0% and 13.0% -
doi:10.1371/journal.pone.0147581.t001
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RCT was compared to the reduction achieved in the IT. In both trials, HbA1c was measured in
the same central laboratory using the HPLC method (normal range: 4.3% to 6.1%; 23.5 to 43.2
mmol/mol).
Other outcome measures were assessed as follows:
Diabetes-related distress was assessed using the German version of the Diabetes Distress
Scale (DDS). The DDS is a well validated and widely applied 17-item self-report scale that eval-
uates the current level of diabetes-related emotional distress for both type 1 and type 2 diabetes
[19].
Empowerment was measured using the German version of the Diabetes Empowerment
Scale, which was developed by Anderson et al. [20].
A German version of the General Self-efficacy Scale [21] was used to assess self-efficacy.
Hypoglycaemia awareness was assessed using the German version [22] of the Hypoglycae-
mia Awareness Scale developed by Clarke et al. [23]. This scale ranges from 0 (maximum hypo-
glycaemia awareness) to 7 (minimum hypoglycaemia awareness), with a score of 4 or higher
suggesting reduced hypoglycaemia awareness.
In addition to defining singular primary and secondary outcomes, we defined a combined
outcome. For this combined outcome, we used baseline data and defined possible clinical
problems. Three problems were defined: (I) Suboptimal glycaemic control was defined by a
HbA1c> 7.5% [24]; (II) Hypoglycaemia problems were defined as having experienced severe
hypoglycaemia during the past 12 months (third party assistance needed) or a score of 4 or
higher on the Hypoglycaemia Awareness Scale (indicating hypoglycaemia unawareness); and
(III) Psychosocial problems due to living with diabetes were defined by a score on the DDS of 3
or higher [25]. In summary, participants could be classified with up to three clinical problems
that indicate a need for structured diabetes education (suboptimal glycaemic control, and/or
hypoglycaemia problems, and/or psychosocial problems).
Demographic and other medical data were retrieved from medical records via case-report-
forms.
Clinical ethics
Both trials were approved by the ethics committee of the German Psychological Association
(approval number: RCT: NH 062010, IT: NH 072012). All patients included in the trials pro-
vided written informed consent.
Statistical analysis
In this comparative effectiveness study, the baseline characteristics of the participants in the IT
and RCT trials were compared. The outcomes of PRIMAS under routine care conditions and
the conditions of the RCT were also compared.
The difference between baseline and 6-month follow-up for HbA1c and the other secondary
outcome parameters were the dependent variables. Condition (delivery in the RCT or IT) was
the independent variable. Student t-tests were used for parametric data, and Chi-Square tests
were used for categorical data.
A multivariate logistic regression analysis was performed with clinical improvement as the
dependent variable. Clinical improvement was defined as improvement in glycaemic control,
and/or hypoglycaemia awareness, and/or psychosocial problems. The independent variable of
interest was trial setting (RCT vs. IT). Additional baseline characteristics were also included,
such as gender, insulin regimen (insulin pump [CSII] therapy vs. multiple daily insulin injec-
tions [MDI]) and z-scores for age, diabetes duration, BMI, HbA1c, hypoglycaemia awareness,
and diabetes-related distress.
Comparative Effectiveness Study: Diabetes Education in Routine Care
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No substitutions of missing data were made. The statistical software programme SYSTAT
12.0 (Systat Software, Inc.; Chicago, IL) was used for the statistical analysis.
Results
In the IT, 179 people with type 1 diabetes from 42 practices were monitored for 6 months. The
data of these participants were compared with those of the 75 participants from the 23 practices
of the RCT who received PRIMAS [18]. The baseline characteristics of the sample that received
PRIMAS in the RCT and IT are described in Table 2.
Baseline characteristics
Participants of the RCT and IT had similar educational statuses and migration backgrounds.
The proportion of CSII-patients and the number of daily insulin injections in the patients with
MDI treatment indicate that the participants were already performing intensive insulin ther-
apy. The RCT included significantly more patients on CSII therapy. Daily blood glucose mea-
surements and insulin demand in the RCT and IT were highly comparable. Furthermore,
hypoglycaemia unawareness and the proportion of people with severe hypoglycaemia (third
party assistance needed for recovery) did not differ between the RCT and IT.
The patients participating in the RCT had a significantly longer diabetes duration than the
participants in the IT. The participants of the RCT reported lower self-efficacy with respect to
the management of diabetes. The baseline results indicate that the participants in the RCT had
more long-term complications than the participants in the IT. Furthermore, the participants in
the RCT were more distressed and had higher HbA1c levels than the participants in the IT, but
these differences were only marginally significant (p< .10).
In a further analysis, we investigated the possible problems that indicate a need toparticipate
in a diabetes education course, distinguishing between people with suboptimal glycaemic
Table 2. Baseline characteristics of the patients in the RCT and IT.
Characteristic
RCT (n = 75) IT (n = 179) p
Age—years (±SD) 45.1 (±13.5) 43.6 (±13.6) .412
% female gender—n (%) 38.7% 46.9% .228
Years of education—mean (±SD) 11.2 (±3.1) 11.1 (±3.0) .916
% with migration background 2.7% 5.6% .319
Mean diabetes duration—years (±SD) 18.8 (±12.3) 13.8 (±12.7) .005
BMI—kg/m2 (±SD) 26.5 (±4.6) 26.0 (±4.7) .435
HbA1c—% (±SD)—mmol/mol (±SD) 8.3 (±1.1) 67
(±12.0)
7.9 (±1.4) 63
(±15.3)
.056
# insulin injections—n (±SD) 5.2 (±1.4) 5.3 (± 1.5) .754
IU/KG—mean (±SD) 0.66 (±0.34) 0.60 (±0.29) .162
% with CSII therapy 25.3% 14.7% .044
# of blood glucose self-tests per day (±SD) 4.7 (±1.6) 5.1 (±1.7) .096
Late complications—n (±SD) 0.8 (±1.3) 0.5 (±0.9) .021
Unawareness score (Range 0–7) 1.8 (±1.7) 1.6 (±1.5) .409
% with severe hypoglycaemic episodes in the 12
months
14.9% 21.3% .245
% with previous structured diabetes education 85.1% 74.3% .061
Diabetes Distress Scale (Range 0–5) 1.3 (±1.0) 1.1 (±0.8) .054
Empowerment (Range 0–33) 24.7 (±6.0) 24.5 (±5.7) .836
Self-efﬁcacy (Range 0–30) 21.9 (±4.7) 23.7 (±6.1) .024
doi:10.1371/journal.pone.0147581.t002
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control (HBA1c>7.5%), hypoglycaemia awareness issues (experience of a severe hypoglycae-
mic episode during the past 12 months or a hypoglycaemia unawareness score 4) or psycho-
social problems due to living with diabetes (diabetes distress scale score 3).
Fig 1 provides an overview of the clinical problems of participants of diabetes education in
the RCT and IT setting. A greater number of the participants in the RCT had HbA1c levels
above 7.5% and reported psychosocial problems.
Outcomes of diabetes education
First, the overall effect of PRIMAS was tested by comparing baseline and follow-up measure-
ments for both trials combined (RCT and IT sample). Six months after participating in PRI-
MAS, significant improvement in glycaemic control (HbA1c: -0.36, 95% CI -0.22 to -0.51,
p< .01), hypoglycaemia awareness (unawareness score: -0.36, 95% CI -0.20-to -0.58, p< .01),
diabetes-related distress (DDS score: -0.18, 95% CI -0.09 to -0.28, p< .01), empowerment
(empowerment score: +2.7, 95% CI 1.7 to 3.7, p< .01) and self-efficacy (self-efficacy score:
+1.1, 95% CI 0.3 to 1.9, p = .01) was observed.
Differences in treatment outcomes: RCT vs. IT
The specific outcomes of participants in the RCT and IT are reported in Table 3. After 6
months, the outcomes of the RCT were highly comparable to those of the IT. The difference
Fig 1. Prevalence of clinical problems (suboptimal glycaemic control, hypoglycaemia problems, and
psychosocial problems) at baseline in the RCT and IT participants.
doi:10.1371/journal.pone.0147581.g001
Table 3. Differences between the outcome effects (baseline– 6-month follow-up) for the RCT and IT.
Outcome RCT (n = 75) IT (n = 179) Between-group difference
(95% CI)
p* Effect size of difference
(95% CI)
HbA1c—% (±SD)—mmol/mol (±SD) (n
missing = 19)
-0.36 (±1.05) - 4.0
(±11.5)
-0.37 (±1.19) - 4.0
(±13.0)
-0.01 (-0.33–0.31) .959 0.01 (-0.29–0.31)
Unawareness score (n missing = 38) -0.51 (±1.42) -0.33 (±1.38) 0.18 (-0.22–0.57) .373 0.13 (-0.16–0.42)
Diabetes Distress Scale (n missing = 34) -0.34 (±0.75) -0.11 (±0.67) 0.23 (0.04–0.43) .021 0.36 (0.06–0.67)
Empowerment (n missing = 35) +2.61 (±5.94) +2.84 (±8.26) -0.23 (-2.36–1.90) .831 -0.03 (-0.34–0.27)
Self-efﬁcacy (n missing = 35) +1.40 (±3.56) +0.93 (±7.34) 0.46 (-1.32–2.24) .609 0.08 (-0.23–0.39)
* Between group differences
doi:10.1371/journal.pone.0147581.t003
Comparative Effectiveness Study: Diabetes Education in Routine Care
PLOS ONE | DOI:10.1371/journal.pone.0147581 January 22, 2016 7 / 12
in the reduction of HbA1c was minimal and far from being significant. Differences in the
improvement of hypoglycaemia unawareness, empowerment, and self-efficacy between the
RCT and IT were also not statistically significant. Therefore, the delivery of PRIMAS in a rou-
tine care setting was not substantially less efficacious than its delivery during the RCT. The
only exception was a significantly greater reduction of diabetes-related distress in the RCT.
However, since significant differences in diabetes-related distress were observed at baseline,
the analysis was adjusted for baseline differences of the DDS scores. The baseline-adjusted
between-group difference did not significantly differ between the RCT and IT (Δ -0.03, 95% CI
-0.19 to 0.12, p = .68).
Table 3 also depicts the effect sizes of the differences in the outcomes achieved in the RCT
compared to the IT. Effect sizes ranging from -0.03 to 0.36 standard deviations are indicative of
rather small to moderate effect sizes.
Impact of trial setting on clinical improvement
In an additional analysis, the impact of the trial setting (RCT vs. IT) on clinical improvement
at the 6-month follow-up was analysed. Clinical improvement was defined as an improvement
in at least one of the clinical outcomes, glycaemic control, hypoglycaemia problems or elevated
diabetes-related distress. A multivariate logistic regression analysis with trial setting (RCT vs.
IT) as the independent variable was performed, and baseline sample characteristics were con-
trolled for (see Fig 2). The multivariate regression model did not show a significant effect of
trial setting (RCT vs. IT) on the odds ratio to achieve clinical improvement in any of the clinical
outcomes. Furthermore, neither the baseline demographic variables, such as age or gender, nor
the medical variables, such as BMI or treatment (CSII vs. MDI), had a significant effect. Inter-
estingly, higher HbA1c values, higher hypoglycaemia unawareness scores and higher diabetes
distress scores increased the likelihood of clinical improvement 6 months after diabetes educa-
tion, regardless of trial setting (RCT vs. IT).
Discussion
This comparative effectiveness analysis of the PRIMAS education programme for type 1 diabe-
tes under RCT and routine care conditions revealed different sample composition between the
Fig 2. Odds ratios for clinical improvement in glycaemic control, hypoglycaemia awareness and/or
diabetes-related distress (continuous variables: odds ratio per 1 standard deviation increase). * p <
.05.
doi:10.1371/journal.pone.0147581.g002
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RCT and IT trials but comparable clinical outcome effects. The setting of the delivery of PRI-
MAS (RCT vs. IT) did not have a significant impact on clinical improvements when baseline
demographic and medical variables were controlled for.
Baseline characteristics
The participants in the RCT setting had a significantly longer diabetes duration, more compli-
cations, lower self-efficacy, marginally more diabetes-related distress, and higher HbA1c levels
than the participants in the IT setting. A selection bias may have influenced the sample compo-
sitions. Patients with a more complicated course of their diabetes seem to be easier to motivate
to participate in an RCT, whereas patients with a less complicated course of their diabetes may
rather volunteer for an observational trial under routine care conditions [24].
The medical problems used as indicators for participation in diabetes education, such as
suboptimal glycaemic control or elevated diabetes-related distress, were significantly more fre-
quent in the RCT sample than in the IT sample. The finding regarding glycaemic control may
have been due to the inclusion criterion of HbA1c> 7.5% [18]. The higher proportion of par-
ticipants with elevated diabetes-related distress observed in the RCT could be attributable to
the more complicated course of their diabetes compared to that of the IT participants (i.e.,
more late complications).
The observed baseline differences are in line with observations made in other comparative
effectiveness studies, which showed that people who seek treatment in observational trials are
younger, have more access to health care and have a better prognosis than people who are not
seeking treatment [25].
Outcomes of diabetes education
Diabetes education with PRIMAS led to a 0.36-percentage-point reduction in HbA1c when
both trials were combined. The overall extent of improvement may be less than in previous
type 1 diabetes education trials [2–5]; however, it has to be taken into account that in early type
1 diabetes education trials, the participants were switched from a conventional insulin regimen
to an intensive insulin treatment, making it difficult to separate the effect of diabetes education
from the impact of the insulin regimen change. In the present analysis, the baseline characteris-
tics suggest that the vast majority of the participants were already on an intensive insulin ther-
apy regimen and had remarkably better glycaemic control at baseline than the participants in
the diabetes education trials cited above. This may have limited the potential for improvement
in glycaemic control in both PRIMAS trials. However, a similar effect regarding HbA1c-reduc-
tion was reported in the implementation trial of the DAFNE programme [26]. After 6 months,
the authors found a reduction in HbA1c of 0.3%. Interestingly, baseline HbA1c for routine care
was 8.5% compared to the 9.4% found in the initial DAFNE RCT [2–5]. Regarding baseline
HbA1c and achieved reduction in HbA1c, the results from DAFNE in a routine care setting are
highly comparable to the results obtained in both PRIMAS trials.
Remarkably, although PRIMAS was able to improve glycaemic control, there was also a sig-
nificant improvement in hypoglycaemia awareness in both trials. This is in line with previous
findings that improvements in glycaemic control within education trials do not necessarily
increase the risk for hypoglycaemia [27]. In addition to metabolic improvements, the partici-
pants of the RCT and IT also reported lower diabetes-related distress and higher empowerment
and self-efficacy. This can be interpreted as an indication that diabetes self-management in
people with type 1 diabetes [8] was positively affected by PRIMAS; a similar effect has been
shown for type 2 diabetes in meta-analyses and reviews [28–30].
Comparative Effectiveness Study: Diabetes Education in Routine Care
PLOS ONE | DOI:10.1371/journal.pone.0147581 January 22, 2016 9 / 12
Differences in treatment outcomes: RCT vs. IT
Comparing the HbA1c reduction for the RCT and IT revealed no substantial differences
between the settings. The mean difference was only 0.01 percentage points. The 95% confi-
dence interval of this difference did not exceed the threshold of 0.4 percentage points, which is
a commonly used threshold to determine clinical non-inferiority with regard to improvements
in glycaemic control [31]. Thus, the results of the IT indicate that with respect to glycaemic
control, PRIMAS was equally effective when delivered in a routine care setting as when it was
delivered in the RCT [18].
In addition, the comparisons of the other outcomes also indicate that the effects of PRIMAS
at the 6-month follow-up that were achieved in the IT were highly comparable to those
achieved in the RCT. Only the reduction of diabetes-related distress was significantly greater in
the RCT than in the IT. At baseline, however, the participants of the RCT already exhibited sig-
nificantly higher distress scores than the participants of the IT. With the exception of the
reduction in diabetes-related distress, the effect sizes of the differences between the RCT and
IT were rather small [32], which corroborates the notion of equal effectiveness. While the base-
line difference may account for the greater reduction of distress in the RCT, a likely explanation
may also be that the elements of PRIMAS that triggered the improvement in distress were less
effective in the IT. This may be attributable to the better training of RCT practices prior to
study start. The better training was due to stricter study SOPs for the delivery of the interven-
tion compared to routine care.
Impact of trial setting on clinical improvement
The results of the multivariate logistic regression analysis showed that clinical improvement in
at least one of the three clinical problems (suboptimal glycaemic control, hypoglycaemia prob-
lems, or elevated distress) was independent of the setting in which PRIMAS was conducted
(RCT vs. IT). Thus, important clinical problems can be addressed and significantly improved
by the PRIMAS programme. Improvement of those problems could be achieved not only in a
controlled RCT environment but also in a routine care setting. Furthermore, the effects of PRI-
MAS were not limited to a specific patient group, as demographic variables were not significant
in the logistic regression analysis.
Not only was there a difference in study setting, there was also a difference in the degree of
specialization of the practices that participated in the RCT and IT. We therefore analysed
whether care level had an impact on the clinical improvement achieved through PRIMAS.
Care level was included in the logistic regression analysis, but it was not a significant predictor
of clinical improvement and did not substantially alter the odds ratios or the significance of the
remaining variables (data not shown). Hence, this result indicates that PRIMAS is equally
effective at the primary and secondary care level.
Limitations and strengths
When interpreting the results of the study, the following limitation should be considered. This
study was a post hoc analysis of results from an RCT and an IT. Although the results suggest
equal effects on key outcomes except diabetes-related distress, the design was not a formal
non-inferiority study [33].
However, comparison of efficacy in an RCT and effectiveness in an IT can provide valuable
insight into the transfer of a diabetes education programme from an artificially controlled
research setting into clinical practice. The IT closely mirrors the clinical practice of diabetes
education with PRIMAS, as it did not include strict eligibility criteria or predefine how the edu-
cation course should be conducted. In addition, not only specialised diabetologists took part in
Comparative Effectiveness Study: Diabetes Education in Routine Care
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the IT but also less-specialised practices at the primary care level. All in all, the generalisability
of this comparative effectiveness study can be considered high because not only did the IT
include a wider range of patients but a more representative range of practices was also used to
conduct PRIMAS.
Conclusion
In summary, this comparative effectiveness analysis showed that the PRIMAS education pro-
gramme for type 1 diabetes can be delivered under conditions of routine care without a loss of
effectiveness compared to that found during its original evaluation in an RCT.
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